Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amryt Pharma Plc ADR (NQ: AMYT ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 11, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Amryt Pharma Plc ADR Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc April 12, 2023 From Amryt Pharma plc Via GlobeNewswire High Court of Justice of England and Wales Sanctions Scheme of Arrangement April 03, 2023 From Amryt Pharma plc Via GlobeNewswire Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici March 22, 2023 From Amryt Pharma plc Via GlobeNewswire AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders February 27, 2023 From Halper Sadeh LLC Via Business Wire AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT February 24, 2023 From Kahn Swick & Foti, LLC Via Business Wire AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 February 16, 2023 From Amryt Pharma plc Via GlobeNewswire AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT January 10, 2023 From Kahn Swick & Foti, LLC Via Business Wire AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders January 09, 2023 From Halper Sadeh LLC Via Business Wire Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc January 08, 2023 From Amryt Pharma plc Via GlobeNewswire Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH January 05, 2023 From Amryt Pharma plc Via GlobeNewswire COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors December 19, 2022 From Amryt Pharma plc Via GlobeNewswire European Commission approves Mycapssa® for the treatment of Acromegaly December 05, 2022 From Amryt Pharma plc Via GlobeNewswire Amryt Announces New Patent for Mycapssa® November 30, 2022 From Amryt Pharma plc Via GlobeNewswire Amryt Reports Q3 2022 Financial and Operational Results November 03, 2022 From Amryt Pharma plc Via GlobeNewswire Amryt Supports Acromegaly Awareness Day 2022 October 31, 2022 From Amryt Pharma plc Via GlobeNewswire The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa October 25, 2022 From Amryt Pharma plc Via GlobeNewswire Amryt Supports Global EB Awareness Week 2022 October 24, 2022 From Amryt Pharma plc Via GlobeNewswire Amryt to Report Q3 2022 Results on November 3, 2022 October 19, 2022 From Amryt Pharma plc Via GlobeNewswire COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly October 18, 2022 From Amryt Pharma plc Via GlobeNewswire Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin) October 17, 2022 From Amryt Pharma plc Via GlobeNewswire Amryt Pharma Plc (NASDAQ:AMYT) Shareholder Notice: Investigation Concerning Possible Wrongdoing May 04, 2022 San Diego, CA -- (SBWIRE) -- 05/04/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Amryt Pharma plc. Via SBWire Amryt Pharma Plc (NASDAQ:AMYT) Investor Notice: Investigation over Possible Violations of Securities Laws March 21, 2022 San Diego, CA -- (SBWIRE) -- 03/21/2022 -- Amryt Pharma plc is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.